__NUXT_JSONP__("/drugs/Galinpepimut-S", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"A peptide cancer vaccine comprised of four peptide chains derived from the Wilms' tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, galinpepimut-S, which is comprised of one WT1-derived peptide (WT-A1) that may stimulate CD8-positive T-cell responses; two WT1 peptides (WT1-427 long, WT1-331 long) that may stimulate CD4-positive T-cell responses; and one modified peptide (WT1-122A1 long) that may stimulate both CD4-positive and CD8-positive T-cells, may elicit a targeted innate immune response against WT1-expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.",fdaUniiCode:"12R66419FZ",identifier:"C161778",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C1663","C1752"],synonyms:["GALINPEPIMUT-S",a,"SLS 001","SLS-001","SLS001","WT-1 Analog Peptide Vaccine SLS-001"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FGalinpepimut-S",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Galinpepimut-S","","2021-10-30T13:35:15.943Z")));